Antipsychotic Drugs Market Size, Share, and Trends 2024 to 2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Antipsychotic Drugs Market 

5.1. COVID-19 Landscape: Antipsychotic Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Antipsychotic Drugs Market, By Therapeutic Class

8.1. Antipsychotic Drugs Market, by Therapeutic Class, 2024-2033

8.1.1. First Generation

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Second Generation

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Third Generation

8.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Antipsychotic Drugs Market, By Disease

9.1. Antipsychotic Drugs Market, by Disease, 2024-2033

9.1.1. Schizophrenia

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Bipolar Disorder

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Unipolar Depression

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Dementia

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Other Diseases

9.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Antipsychotic Drugs Market, By Drug 

10.1. Antipsychotic Drugs Market, by Drug, 2024-2033

10.1.1. Risperidone

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Quetiapine

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Olanzapine

10.1.3.1. Market Revenue and Forecast (2021-2033)

10.1.4. Aripiprazole

10.1.4.1. Market Revenue and Forecast (2021-2033)

10.1.5. Others

10.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 11. Global Antipsychotic Drugs Market, By Distribution Channel 

11.1. Antipsychotic Drugs Market, by Distribution Channel, 2024-2033

11.1.1. Hospital Pharmacies

11.1.1.1. Market Revenue and Forecast (2021-2033)

11.1.2. Drug Stores & Retail Pharmacies

11.1.2.1. Market Revenue and Forecast (2021-2033)

11.1.3. Online Pharmacies

11.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 12. Global Antipsychotic Drugs Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)

12.1.2. Market Revenue and Forecast, by Disease (2021-2033)

12.1.3. Market Revenue and Forecast, by Drug (2021-2033)

12.1.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)

12.1.5.2. Market Revenue and Forecast, by Disease (2021-2033)

12.1.5.3. Market Revenue and Forecast, by Drug (2021-2033)

12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)

12.1.6.2. Market Revenue and Forecast, by Disease (2021-2033)

12.1.6.3. Market Revenue and Forecast, by Drug (2021-2033)

12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)

12.2.2. Market Revenue and Forecast, by Disease (2021-2033)

12.2.3. Market Revenue and Forecast, by Drug (2021-2033)

12.2.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)

12.2.5.2. Market Revenue and Forecast, by Disease (2021-2033)

12.2.5.3. Market Revenue and Forecast, by Drug (2021-2033)

12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)

12.2.6.2. Market Revenue and Forecast, by Disease (2021-2033)

12.2.6.3. Market Revenue and Forecast, by Drug (2021-2033)

12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)

12.2.7.2. Market Revenue and Forecast, by Disease (2021-2033)

12.2.7.3. Market Revenue and Forecast, by Drug (2021-2033)

12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)

12.2.8.2. Market Revenue and Forecast, by Disease (2021-2033)

12.2.8.3. Market Revenue and Forecast, by Drug (2021-2033)

12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)

12.3.2. Market Revenue and Forecast, by Disease (2021-2033)

12.3.3. Market Revenue and Forecast, by Drug (2021-2033)

12.3.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)

12.3.5.2. Market Revenue and Forecast, by Disease (2021-2033)

12.3.5.3. Market Revenue and Forecast, by Drug (2021-2033)

12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)

12.3.6.2. Market Revenue and Forecast, by Disease (2021-2033)

12.3.6.3. Market Revenue and Forecast, by Drug (2021-2033)

12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)

12.3.7.2. Market Revenue and Forecast, by Disease (2021-2033)

12.3.7.3. Market Revenue and Forecast, by Drug (2021-2033)

12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)

12.3.8.2. Market Revenue and Forecast, by Disease (2021-2033)

12.3.8.3. Market Revenue and Forecast, by Drug (2021-2033)

12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)

12.4.2. Market Revenue and Forecast, by Disease (2021-2033)

12.4.3. Market Revenue and Forecast, by Drug (2021-2033)

12.4.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)

12.4.5.2. Market Revenue and Forecast, by Disease (2021-2033)

12.4.5.3. Market Revenue and Forecast, by Drug (2021-2033)

12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)

12.4.6.2. Market Revenue and Forecast, by Disease (2021-2033)

12.4.6.3. Market Revenue and Forecast, by Drug (2021-2033)

12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)

12.4.7.2. Market Revenue and Forecast, by Disease (2021-2033)

12.4.7.3. Market Revenue and Forecast, by Drug (2021-2033)

12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)

12.4.8.2. Market Revenue and Forecast, by Disease (2021-2033)

12.4.8.3. Market Revenue and Forecast, by Drug (2021-2033)

12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)

12.5.2. Market Revenue and Forecast, by Disease (2021-2033)

12.5.3. Market Revenue and Forecast, by Drug (2021-2033)

12.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)

12.5.5.2. Market Revenue and Forecast, by Disease (2021-2033)

12.5.5.3. Market Revenue and Forecast, by Drug (2021-2033)

12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Therapeutic Class (2021-2033)

12.5.6.2. Market Revenue and Forecast, by Disease (2021-2033)

12.5.6.3. Market Revenue and Forecast, by Drug (2021-2033)

12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2021-2033)

Chapter 13. Company Profiles

13.1. Eli Lily and Company

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. AstraZeneca plc

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. GlaxoSmithKline plc

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Johnson & Johnson

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Otsuka Pharmaceutical Co, Ltd.

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Pfizer Inc

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. AbbVie Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Bristol-Myers Squibb

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Teva Pharmaceuticals

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Dr. Reddy's Laboratories

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms